Bioxytran (BIXT) EPS (Basic) Growth (3y) (2014 - 2026)
Bioxytran (BIXT) EPS (Basic) Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | -38.31% |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | 21.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.64% |
| Dec 31, 2025 | 8.90% |
| Sep 30, 2025 | -22.10% |
| Jun 30, 2025 | 27.44% |
| Mar 31, 2025 | -22.79% |
| Dec 31, 2024 | 17.80% |
| Sep 30, 2024 | 10.46% |
| Jun 30, 2024 | 24.41% |
| Mar 31, 2024 | 39.85% |
| Dec 31, 2023 | -0.37% |
| Sep 30, 2023 | -58.37% |
| Jun 30, 2023 | -5.51% |
| Mar 31, 2023 | -2.26% |
| Dec 31, 2022 | 0.96% |
| Sep 30, 2022 | 44.59% |
| Jun 30, 2022 | -55.18% |
| Mar 31, 2022 | -54.10% |
| Dec 31, 2021 | -49.68% |
| Sep 30, 2021 | -97.85% |
| Jun 30, 2021 | -1,407.71% |